Nutrition Research最新文献

英文中文

Ellagic acid as a potential therapeutic agent in metabolic syndrome: A systematic review and meta-analysis of glycemic control markers and kidney function tests in animal and clinical studies 鞣花酸作为代谢综合征的潜在治疗剂：动物和临床研究中血糖控制指标和肾功能试验的系统回顾和荟萃分析

IF 3.1 3区医学 Q2 NUTRITION & DIETETICS

Nutrition Research

Pub Date : 2025-11-01 DOI: 10.1016/j.nutres.2025.10.001

Kornvipa Settakorn , Ratchanon Inpan , Mingkwan Na Takuathung , Nut Koonrungsesomboon

Metabolic syndrome comprises a cluster of abnormal metabolic markers, including hyperglycemia, insulin resistance, hypertension, obesity, and dyslipidemia, that increase the risk of diabetes mellitus, cardiovascular diseases, and associated complications. Prolonged hyperglycemia results in microvascular complications such as nephropathy, while other abnormal metabolic markers contribute to progressive kidney dysfunction. Ellagic acid (EA) exhibits antihyperglycemia and nephroprotective effects. This study evaluated the effects of EA on glycemic control markers and kidney function tests in animal and human models with abnormal metabolic markers and preobesity. Comprehensive searches were conducted in Embase, Scopus, PubMed, and the Cochrane Library. Data were synthesized using meta-analysis, and risk of bias was assessed using SYRCLE’s tool for animal studies and the Risk of Bias 2 tool for human studies. The certainty of evidence in human studies was evaluated using the GRADE approach. Meta-analysis revealed that EA significantly reduced blood glucose concentration (standardized mean differences = –4.03; 95% confidence intervals = –5.02 to –3.04; P < .0001) and improved insulin resistance by lowering homeostatic model assessment of insulin resistance (standardized mean differences = –2.48, 95% confidence intervals =–3.21 to –1.76, P < .0001) in animal studies. However, EA did not significantly affect glucose concentration, insulin, and homeostatic model assessment of insulin resistance in human studies. EA significantly decreased blood urea nitrogen and creatinine in animal studies. Overall, findings from animal studies suggest that EA may have therapeutic potential for improving glycemic control and mitigating kidney complications in metabolic syndrome. However, the absence of significant effects in humans highlights the need for high-quality clinical trials to determine its translational potential.

代谢综合征包括一系列异常代谢标志物，包括高血糖、胰岛素抵抗、高血压、肥胖和血脂异常，它们增加了糖尿病、心血管疾病和相关并发症的风险。长期高血糖可导致微血管并发症，如肾病，而其他异常代谢标志物可导致进行性肾功能障碍。鞣花酸（EA）具有抗高血糖和肾保护作用。本研究评估了EA对代谢标志物异常和肥胖前期动物和人模型的血糖控制指标和肾功能测试的影响。在Embase、Scopus、PubMed和Cochrane图书馆中进行了全面的检索。使用荟萃分析对数据进行综合，使用sycle的动物研究工具和人类研究的风险偏倚2工具评估偏倚风险。使用GRADE方法评估人体研究证据的确定性。荟萃分析显示，在动物研究中，EA可显著降低血糖浓度（标准化平均差异= -4.03；95%置信区间= -5.02至-3.04;P < 0.0001），并通过降低胰岛素抵抗的稳态模型评估（标准化平均差异= -2.48,95%置信区间= -3.21至-1.76,P < 0.0001）改善胰岛素抵抗。然而，在人体研究中，EA对葡萄糖浓度、胰岛素和胰岛素抵抗的稳态模型评估没有显著影响。在动物实验中，EA显著降低血尿素氮和肌酐。总的来说，动物研究结果表明，EA可能具有改善血糖控制和减轻代谢综合征肾脏并发症的治疗潜力。然而，在人类中没有显著的影响，强调需要高质量的临床试验来确定其转化潜力。

{"title":"Ellagic acid as a potential therapeutic agent in metabolic syndrome: A systematic review and meta-analysis of glycemic control markers and kidney function tests in animal and clinical studies","authors":"Kornvipa Settakorn , Ratchanon Inpan , Mingkwan Na Takuathung , Nut Koonrungsesomboon","doi":"10.1016/j.nutres.2025.10.001","DOIUrl":"10.1016/j.nutres.2025.10.001","url":null,"abstract":"<div><div>Metabolic syndrome comprises a cluster of abnormal metabolic markers, including hyperglycemia, insulin resistance, hypertension, obesity, and dyslipidemia, that increase the risk of diabetes mellitus, cardiovascular diseases, and associated complications. Prolonged hyperglycemia results in microvascular complications such as nephropathy, while other abnormal metabolic markers contribute to progressive kidney dysfunction. Ellagic acid (EA) exhibits antihyperglycemia and nephroprotective effects. This study evaluated the effects of EA on glycemic control markers and kidney function tests in animal and human models with abnormal metabolic markers and preobesity. Comprehensive searches were conducted in Embase, Scopus, PubMed, and the Cochrane Library. Data were synthesized using meta-analysis, and risk of bias was assessed using SYRCLE’s tool for animal studies and the Risk of Bias 2 tool for human studies. The certainty of evidence in human studies was evaluated using the GRADE approach. Meta-analysis revealed that EA significantly reduced blood glucose concentration (standardized mean differences = –4.03; 95% confidence intervals = –5.02 to –3.04; <em>P</em> < .0001) and improved insulin resistance by lowering homeostatic model assessment of insulin resistance (standardized mean differences = –2.48, 95% confidence intervals =–3.21 to –1.76, <em>P</em> < .0001) in animal studies. However, EA did not significantly affect glucose concentration, insulin, and homeostatic model assessment of insulin resistance in human studies. EA significantly decreased blood urea nitrogen and creatinine in animal studies. Overall, findings from animal studies suggest that EA may have therapeutic potential for improving glycemic control and mitigating kidney complications in metabolic syndrome. However, the absence of significant effects in humans highlights the need for high-quality clinical trials to determine its translational potential.</div></div>","PeriodicalId":19245,"journal":{"name":"Nutrition Research","volume":"143 ","pages":"Pages 89-100"},"PeriodicalIF":3.1,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145418287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Including malnourished siblings in treatment improves nutritional outcomes for children with sickle cell anemia in Northern Nigeria: Results from a feasibility trial 将营养不良的兄弟姐妹纳入治疗可改善尼日利亚北部镰状细胞性贫血儿童的营养结局：可行性试验的结果。

IF 3.1 3区医学 Q2 NUTRITION & DIETETICS

Nutrition Research

Pub Date : 2025-10-18 DOI: 10.1016/j.nutres.2025.10.006

Hassan Adam Murtala , Shehu U. Abdullahi , Safiya Gambo , Halima Kabir , Khadija A. Shamsu , Garba Gwarzo , Sari A. Acra , Virginia A. Stallings , Mark Rodeghier , Michael R. DeBaun , Lauren J. Klein

Best treatment approaches for malnutrition in children with sickle cell anemia (SCA) remain underexplored. We hypothesized that (1) children with SCA (CwSCA) enrolled in a malnutrition trial alongside their non-SCA siblings would experience greater nutritional improvements than those without an enrolled sibling and (2) enrolled malnourished siblings without SCA would have higher baseline nutritional status and greater improvements in nutritional status than CwSCA. We tested these hypotheses as part of a randomized controlled feasibility trial at 2 medical centers in northern Nigeria, a low-resource setting with a significant burden of malnutrition and SCA. Participants included 108 CwSCA (5-12 years) with severe malnutrition (body mass index (BMI) z-score <-3.0), 21 of whom had an enrolled sibling (Sibling) with severe malnutrition but without SCA (5-12 years, n = 22). All participants received daily ready-to-use therapeutic food (RUTF) for 12 weeks. CwSCA with a Sibling had a higher mean BMI z-score change than CwSCA without a Sibling (0.8 vs 0.4, P = .003). The mean baseline BMI z-scores for the CwSCA (-3.7) were comparable to those of their Siblings (-3.6; P = .47). Improvement in BMI z-score was similar between CwSCA and their malnourished siblings without SCA. In conclusion, our findings suggest that including malnourished siblings in nutritional interventions enhances outcomes for CwSCA. We postulate that the additional calories delivered by co-treating siblings reduce intrahousehold competition for RUTF, thereby allowing CwSCA to consume a greater share of the therapeutic food. This trial was registered at clinicaltrials.gov (NCT03634488).

镰状细胞性贫血（SCA）儿童营养不良的最佳治疗方法仍未得到充分探索。我们假设：(1)与非SCA兄弟姐妹一起参加营养不良试验的SCA （CwSCA）儿童比没有参加试验的兄弟姐妹有更大的营养改善；(2)与CwSCA相比，没有SCA的营养不良兄弟姐妹有更高的基线营养状况和更大的营养状况改善。作为随机对照可行性试验的一部分，我们在尼日利亚北部的两个医疗中心测试了这些假设，这是一个资源匮乏的环境，营养不良和SCA负担沉重。参与者包括108名患有严重营养不良（身体质量指数（BMI） z-score）的CwSCA（5-12岁）

{"title":"Including malnourished siblings in treatment improves nutritional outcomes for children with sickle cell anemia in Northern Nigeria: Results from a feasibility trial","authors":"Hassan Adam Murtala , Shehu U. Abdullahi , Safiya Gambo , Halima Kabir , Khadija A. Shamsu , Garba Gwarzo , Sari A. Acra , Virginia A. Stallings , Mark Rodeghier , Michael R. DeBaun , Lauren J. Klein","doi":"10.1016/j.nutres.2025.10.006","DOIUrl":"10.1016/j.nutres.2025.10.006","url":null,"abstract":"<div><div>Best treatment approaches for malnutrition in children with sickle cell anemia (SCA) remain underexplored. We hypothesized that (1) children with SCA (CwSCA) enrolled in a malnutrition trial alongside their non-SCA siblings would experience greater nutritional improvements than those without an enrolled sibling and (2) enrolled malnourished siblings without SCA would have higher baseline nutritional status and greater improvements in nutritional status than CwSCA. We tested these hypotheses as part of a randomized controlled feasibility trial at 2 medical centers in northern Nigeria, a low-resource setting with a significant burden of malnutrition and SCA. Participants included 108 CwSCA (5-12 years) with severe malnutrition (body mass index (BMI) z-score <-3.0), 21 of whom had an enrolled sibling (Sibling) with severe malnutrition but without SCA (5-12 years, n = 22). All participants received daily ready-to-use therapeutic food (RUTF) for 12 weeks. CwSCA with a Sibling had a higher mean BMI z-score change than CwSCA without a Sibling (0.8 vs 0.4, <em>P</em> = .003). The mean baseline BMI z-scores for the CwSCA (-3.7) were comparable to those of their Siblings (-3.6; <em>P</em> = .47). Improvement in BMI z-score was similar between CwSCA and their malnourished siblings without SCA. In conclusion, our findings suggest that including malnourished siblings in nutritional interventions enhances outcomes for CwSCA. We postulate that the additional calories delivered by co-treating siblings reduce intrahousehold competition for RUTF, thereby allowing CwSCA to consume a greater share of the therapeutic food. This trial was registered at clinicaltrials.gov (NCT03634488).</div></div>","PeriodicalId":19245,"journal":{"name":"Nutrition Research","volume":"144 ","pages":"Pages 32-37"},"PeriodicalIF":3.1,"publicationDate":"2025-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145550234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Influence of the CYP1A2 genotype on the exercise performance of physically active individuals under caffeine supplementation: a systematic review CYP1A2基因型对咖啡因补充下运动个体运动表现的影响：一项系统综述

IF 3.1 3区医学 Q2 NUTRITION & DIETETICS

Nutrition Research

Pub Date : 2025-10-16 DOI: 10.1016/j.nutres.2025.10.005

Gabriel Peres Messenburger , Fernanda Ferreira Nuñez , Olavo Porepp , Lucas das Neves Collares , Felipe Mendes Delpino , Carlos Castilho de Barros , Simone Pieniz

This study aims to evaluate the influence of the CYP1A2 genotype on the exercise performance of athletes and physically active individuals with caffeine supplementation. We followed the recommendations of the Preferred Reporting Items for Systematic Reviews and Meta-Analysis. The search was performed up to May 2025 and included the following databases: PubMed, EMBASE, Scopus, Web of Science, Cochrane Central Register of Controlled Trials, CINAHL, LILACS, and SPORTDiscus. Only randomized clinical trials evaluating the effects of caffeine supplementation and the influence of the CYP1A2 genotype on exercise performance were included. The risk of bias was evaluated using the updated version of the Cochrane tool for assessing bias risk in randomized trials (RoB 2). We included 19 studies, involving 732 participants, and published between 2012 and 2024. Dosages of caffeine supplementation ranged from 2 to 9 mg/kg. Although there is no consensus among all studies, caffeine supplementation has shown positive results in sports performance in individuals with the AA genotype, as well as positive for AC individuals with smaller effect sizes, and null or negative for individuals with the CC genotype. The majority (84%) of the included studies were classified as “some concerns” in our risk of bias analysis, with only two studies classified as having a low risk of bias. Caffeine may enhance athletic performance in various sports modalities and physical tests in individuals with the AA genotype, may also demonstrate marginal improvement in AC individuals, and has null or detrimental effects on individuals with the CC genotype.

本研究旨在评估CYP1A2基因型对补充咖啡因的运动员和体力活动者运动表现的影响。我们遵循了系统评价和荟萃分析的首选报告项目的建议。检索截止到2025年5月，包括以下数据库：PubMed、EMBASE、Scopus、Web of Science、Cochrane Central Register of Controlled Trials、CINAHL、LILACS和SPORTDiscus。仅纳入了评估咖啡因补充效果和CYP1A2基因型对运动表现影响的随机临床试验。使用更新版本的Cochrane随机试验偏倚风险评估工具对偏倚风险进行评估（RoB 2）。我们纳入了19项研究，涉及732名参与者，发表于2012年至2024年之间。咖啡因补充剂量为2至9毫克/公斤。虽然在所有的研究中没有达成共识，但咖啡因补充剂对AA基因型个体的运动表现有积极的影响，对AC个体的影响较小，对CC基因型个体的影响为零或阴性。在我们的偏倚风险分析中，大多数（84%）纳入的研究被归类为“一些关注”，只有两项研究被归类为低偏倚风险。咖啡因可以提高AA基因型个体在各种运动方式和体能测试中的运动表现，也可能在AC基因型个体中显示出边际改善，而对CC基因型个体没有影响或有害影响。

{"title":"Influence of the CYP1A2 genotype on the exercise performance of physically active individuals under caffeine supplementation: a systematic review","authors":"Gabriel Peres Messenburger , Fernanda Ferreira Nuñez , Olavo Porepp , Lucas das Neves Collares , Felipe Mendes Delpino , Carlos Castilho de Barros , Simone Pieniz","doi":"10.1016/j.nutres.2025.10.005","DOIUrl":"10.1016/j.nutres.2025.10.005","url":null,"abstract":"<div><div>This study aims to evaluate the influence of the CYP1A2 genotype on the exercise performance of athletes and physically active individuals with caffeine supplementation. We followed the recommendations of the Preferred Reporting Items for Systematic Reviews and Meta-Analysis. The search was performed up to May 2025 and included the following databases: PubMed, EMBASE, Scopus, Web of Science, Cochrane Central Register of Controlled Trials, CINAHL, LILACS, and SPORTDiscus. Only randomized clinical trials evaluating the effects of caffeine supplementation and the influence of the CYP1A2 genotype on exercise performance were included. The risk of bias was evaluated using the updated version of the Cochrane tool for assessing bias risk in randomized trials (RoB 2). We included 19 studies, involving 732 participants, and published between 2012 and 2024. Dosages of caffeine supplementation ranged from 2 to 9 mg/kg. Although there is no consensus among all studies, caffeine supplementation has shown positive results in sports performance in individuals with the AA genotype, as well as positive for AC individuals with smaller effect sizes, and null or negative for individuals with the CC genotype. The majority (84%) of the included studies were classified as “some concerns” in our risk of bias analysis, with only two studies classified as having a low risk of bias. Caffeine may enhance athletic performance in various sports modalities and physical tests in individuals with the AA genotype, may also demonstrate marginal improvement in AC individuals, and has null or detrimental effects on individuals with the CC genotype.</div></div>","PeriodicalId":19245,"journal":{"name":"Nutrition Research","volume":"144 ","pages":"Pages 16-31"},"PeriodicalIF":3.1,"publicationDate":"2025-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145482634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Probiotic-fermented milk alleviates hypertension in preeclampsia rats and is associated with increases in branched fatty acid esters of hydroxy fatty acids 益生菌发酵乳可减轻子痫前期大鼠的高血压，并与羟基脂肪酸支链脂肪酸酯的增加有关

IF 3.1 3区医学 Q2 NUTRITION & DIETETICS

Nutrition Research

Pub Date : 2025-10-13 DOI: 10.1016/j.nutres.2025.10.004

Tingyi Ke, Tiemin Jiang, Haiyun Li, Xinhong Dong, Hock Eng Khoo

Branched fatty acid esters of hydroxy fatty acids (FAHFAs), a newly-discovered class of endogenous lipids closely associated with obesity, cardiovascular disease, and aging, are potential drug candidates or targets for the prevention and treatment of related conditions. The antihypertensive potential of probiotic-fermented milk has been recognized, but its relevance to preeclampsia (PE) is unclear. It was hypothesized that probiotic-fermented milk could reduce blood pressure in PE rats and influence the contents of FAHFAs, with FAHFAs potentially playing a critical role in this process. To test this hypothesis, the PE rat model was constructed using L-NAME (125 mg/kg), and probiotic-fermented milk (20 mg/kg) was administered for a total of 21 d. Metagenomic sequencing and LC—MS/MS based metabolomics were used. Probiotic-fermented milk substantially attenuated hypertension in PE rats, with an efficacy comparable to that of labetalol (4 mg/kg). Probiotic-fermented milk significantly increased the contents of specific FAHFAs (e.g., 18:0/20:2, 16:0/18:2) in the gut and serum (P < .05) and FAHFAs was negatively correlated with blood pressure (P < .05). Probiotic-fermented milk regulated the composition of gut microbiota (increasing Lactiplantibacillus and Staphylococcus and decreasing Methanobrevibacter and Limosilactobacillus), and down-regulated purine, glyoxylate/dicarboxylate, and amino metabolism, and the one-carbon pool produced by folate. These metabolic shifts were strongly correlated with the gut microbiota and FAHFAs. These results indicate that probiotic-fermented milk alleviates hypertension in PE rats, potentially mediated by FAHFAs. This study provides foundational evidence for the antihypertensive mechanism of probiotic-fermented milk in preeclampsia and supports the development of novel strategies for its prevention and treatment.

羟基脂肪酸支链脂肪酸酯（FAHFAs）是一类新发现的内源性脂类，与肥胖、心血管疾病和衰老密切相关，是预防和治疗相关疾病的潜在候选药物或靶点。益生菌发酵乳的降压潜力已得到认可，但其与子痫前期（PE）的相关性尚不清楚。据推测，益生菌发酵乳可以降低PE大鼠的血压并影响FAHFAs的含量，而FAHFAs可能在这一过程中发挥关键作用。为了验证这一假设，我们使用L-NAME （125 mg/kg）构建PE大鼠模型，并给予益生菌发酵乳（20 mg/kg）共21 d。采用元基因组测序和LC-MS /MS代谢组学方法。益生菌发酵乳可显著减轻PE大鼠的高血压，其疗效与拉贝他洛尔（4mg /kg）相当。益生菌发酵乳显著提高了肠道和血清中特定FAHFAs含量（如18:0/20:2、16:0/18:2）（P < 0.05），且与血压呈负相关（P < 0.05）。益生菌发酵乳调节了肠道菌群组成（乳酸杆菌和葡萄球菌增加，甲烷杆菌和乳酸杆菌减少），下调了嘌呤、乙醛酸/二羧酸盐、氨基代谢和叶酸产生的单碳库。这些代谢变化与肠道微生物群和fahfa密切相关。这些结果表明，益生菌发酵乳可以减轻PE大鼠的高血压，可能是由fahfa介导的。本研究为益生菌发酵乳在子痫前期的降压机制提供了基础证据，并为其预防和治疗的新策略的开发提供了支持。

{"title":"Probiotic-fermented milk alleviates hypertension in preeclampsia rats and is associated with increases in branched fatty acid esters of hydroxy fatty acids","authors":"Tingyi Ke, Tiemin Jiang, Haiyun Li, Xinhong Dong, Hock Eng Khoo","doi":"10.1016/j.nutres.2025.10.004","DOIUrl":"10.1016/j.nutres.2025.10.004","url":null,"abstract":"<div><div>Branched fatty acid esters of hydroxy fatty acids (FAHFAs), a newly-discovered class of endogenous lipids closely associated with obesity, cardiovascular disease, and aging, are potential drug candidates or targets for the prevention and treatment of related conditions. The antihypertensive potential of probiotic-fermented milk has been recognized, but its relevance to preeclampsia (PE) is unclear. It was hypothesized that probiotic-fermented milk could reduce blood pressure in PE rats and influence the contents of FAHFAs, with FAHFAs potentially playing a critical role in this process. To test this hypothesis, the PE rat model was constructed using L-NAME (125 mg/kg), and probiotic-fermented milk (20 mg/kg) was administered for a total of 21 d. Metagenomic sequencing and LC—MS/MS based metabolomics were used. Probiotic-fermented milk substantially attenuated hypertension in PE rats, with an efficacy comparable to that of labetalol (4 mg/kg). Probiotic-fermented milk significantly increased the contents of specific FAHFAs (e.g., 18:0/20:2, 16:0/18:2) in the gut and serum (<em>P</em> < .05) and FAHFAs was negatively correlated with blood pressure (<em>P</em> < .05). Probiotic-fermented milk regulated the composition of gut microbiota (increasing <em>Lactiplantibacillus</em> and <em>Staphylococcus</em> and decreasing <em>Methanobrevibacter</em> and <em>Limosilactobacillus</em>), and down-regulated purine, glyoxylate/dicarboxylate, and amino metabolism, and the one-carbon pool produced by folate. These metabolic shifts were strongly correlated with the gut microbiota and FAHFAs. These results indicate that probiotic-fermented milk alleviates hypertension in PE rats, potentially mediated by FAHFAs. This study provides foundational evidence for the antihypertensive mechanism of probiotic-fermented milk in preeclampsia and supports the development of novel strategies for its prevention and treatment.</div></div>","PeriodicalId":19245,"journal":{"name":"Nutrition Research","volume":"144 ","pages":"Pages 1-15"},"PeriodicalIF":3.1,"publicationDate":"2025-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145442277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

David Kritchevsky Graduate Student Award for Nutrition Research 大卫·克里切夫斯基营养研究研究生奖

IF 3.1 3区医学 Q2 NUTRITION & DIETETICS

Nutrition Research

Pub Date : 2025-10-01 DOI: 10.1016/S0271-5317(25)00129-0

引用次数: 0

Claims of group-level accuracy for bioelectrical impedance analysis in paediatric obesity: a cautionary note 儿童肥胖的生物电阻抗分析的群体水平准确性的声明：一个警告。

IF 3.1 3区医学 Q2 NUTRITION & DIETETICS

Nutrition Research

Pub Date : 2025-10-01 DOI: 10.1016/j.nutres.2025.07.002

Jaz Lyons-Reid , Leigh C. Ward , Jo Secher , Mohammad Shahbaz , Benjamin B. Albert , Wayne S. Cutfield , José G.B. Derraik

引用次数: 0

Bridging nutritional mechanisms and global challenges: The 2024 David Kritchevsky award winners 弥合营养机制和全球挑战：2024年大卫·克里切夫斯基奖得主。

IF 3.1 3区医学 Q2 NUTRITION & DIETETICS

Nutrition Research

Pub Date : 2025-10-01 DOI: 10.1016/j.nutres.2025.07.005

Richard S Bruno

引用次数: 0

Higher dietary n - 3 PUFA and fiber intake are associated with longer leukocyte telomere length: Evidence from a substitution model analysis in the UK Biobank 较高的膳食n - 3 PUFA和纤维摄入量与较长的白细胞端粒长度相关：来自英国生物银行替代模型分析的证据。

IF 3.1 3区医学 Q2 NUTRITION & DIETETICS

Nutrition Research

Pub Date : 2025-10-01 DOI: 10.1016/j.nutres.2025.08.009

Vasiliki Bountziouka , Christopher P. Nelson , Veryan Codd , Nilesh J. Samani

Telomere attrition is a biomarker of cellular aging, influenced by lifestyle and dietary exposures. The specific role of macronutrient composition, particularly polyunsaturated fatty acids (PUFAs), in telomere dynamics remains insufficiently explored. We hypothesized that higher intake of specific macronutrients, particularly PUFAs, would be positively associated with leukocyte telomere length (LTL). In this cross-sectional study of 143,553 UK Biobank participants aged 40-69 years, we examined associations between macronutrient intake and standardized LTL (z-LTL), measured as the log-transformed telomere repeat to single-copy gene ratio. Dietary intake was assessed using repeated 24-hour web-based dietary recalls. Multivariable linear regression models were used to estimate associations between macronutrients (% of total energy intake) and z-LTL, adjusting for demographic, lifestyle, and clinical covariates. Effect estimates were translated into age-equivalent changes in LTL. Carbohydrate and total fat intake were positively associated with z-LTL, corresponding to age-related LTL differences of approximately 30-40 days. In energy substitution models, n - 3 PUFA intake showed a stronger positive association with z-LTL than other fats, with adherence to recommended intake associated with differences equivalent to over 2 years (P < .0001) of age-related telomere shortening, whereas no evidence of an association for MUFA was observed. Energy-adjusted fibre intake was associated with an age-related change of LTL equivalent to 1 year (P < .0001). These findings suggest that dietary composition, particularly n - 3 PUFA intake, may be linked with LTL in a manner consistent with healthier cellular aging. Further longitudinal and experimental studies are needed to confirm these associations and explore their implications for dietary guidance.

端粒磨损是细胞衰老的生物标志物，受生活方式和饮食暴露的影响。宏量营养素组成的具体作用，特别是多不饱和脂肪酸（PUFAs），在端粒动力学仍未充分探讨。我们假设摄入更多的特定常量营养素，特别是PUFAs，与白细胞端粒长度（LTL）呈正相关。在这项对143,553名年龄在40-69岁之间的英国生物银行参与者的横断面研究中，我们检查了常量营养素摄入量与标准化LTL （z-LTL）之间的关系，以对数转化端粒重复与单拷贝基因比率来测量。通过重复的24小时基于网络的饮食回顾来评估饮食摄入量。多变量线性回归模型用于估计宏量营养素（占总能量摄入的百分比）与z-LTL之间的关系，并对人口统计学、生活方式和临床协变量进行了调整。效应估计被转化为LTL的年龄等效变化。碳水化合物和总脂肪摄入量与z-LTL呈正相关，与年龄相关的LTL差异约为30-40天。在能量替代模型中，与其他脂肪相比，n - 3 PUFA摄入量与z-LTL表现出更强的正相关，坚持推荐摄入量与年龄相关的端粒缩短的差异相当于超过2年（P < 0.0001），而未观察到与MUFA相关的证据。能量调节纤维摄入量与年龄相关的LTL变化（相当于1年）相关（P < 0.0001）。这些发现表明，饮食成分，特别是n - 3 PUFA摄入量，可能与LTL以一种与更健康的细胞衰老一致的方式相关。需要进一步的纵向和实验研究来证实这些关联，并探讨其对饮食指导的影响。

{"title":"Higher dietary n - 3 PUFA and fiber intake are associated with longer leukocyte telomere length: Evidence from a substitution model analysis in the UK Biobank","authors":"Vasiliki Bountziouka , Christopher P. Nelson , Veryan Codd , Nilesh J. Samani","doi":"10.1016/j.nutres.2025.08.009","DOIUrl":"10.1016/j.nutres.2025.08.009","url":null,"abstract":"<div><div>Telomere attrition is a biomarker of cellular aging, influenced by lifestyle and dietary exposures. The specific role of macronutrient composition, particularly polyunsaturated fatty acids (PUFAs), in telomere dynamics remains insufficiently explored. We hypothesized that higher intake of specific macronutrients, particularly PUFAs, would be positively associated with leukocyte telomere length (LTL). In this cross-sectional study of 143,553 UK Biobank participants aged 40-69 years, we examined associations between macronutrient intake and standardized LTL (z-LTL), measured as the log-transformed telomere repeat to single-copy gene ratio. Dietary intake was assessed using repeated 24-hour web-based dietary recalls. Multivariable linear regression models were used to estimate associations between macronutrients (% of total energy intake) and z-LTL, adjusting for demographic, lifestyle, and clinical covariates. Effect estimates were translated into age-equivalent changes in LTL. Carbohydrate and total fat intake were positively associated with z-LTL, corresponding to age-related LTL differences of approximately 30-40 days. In energy substitution models, <em>n</em> - 3 PUFA intake showed a stronger positive association with z-LTL than other fats, with adherence to recommended intake associated with differences equivalent to over 2 years (<em>P < .</em>0001) of age-related telomere shortening, whereas no evidence of an association for MUFA was observed. Energy-adjusted fibre intake was associated with an age-related change of LTL equivalent to 1 year (<em>P < .</em>0001). These findings suggest that dietary composition, particularly <em>n</em> - 3 PUFA intake, may be linked with LTL in a manner consistent with healthier cellular aging. Further longitudinal and experimental studies are needed to confirm these associations and explore their implications for dietary guidance.</div></div>","PeriodicalId":19245,"journal":{"name":"Nutrition Research","volume":"142 ","pages":"Pages 63-75"},"PeriodicalIF":3.1,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145186263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The devil is in the details: Reassessing an isolation attempt reveals methodological breaches in dietary inorganic nitrate research 细节决定成败：重新评估一项分离试验揭示了膳食无机硝酸盐研究方法上的漏洞。

IF 3.1 3区医学 Q2 NUTRITION & DIETETICS

Nutrition Research

Pub Date : 2025-10-01 DOI: 10.1016/j.nutres.2025.08.008

Jonas Benjamim

引用次数: 0

Editorial office and Board Members 编辑部和董事会成员

IF 3.1 3区医学 Q2 NUTRITION & DIETETICS

Nutrition Research

Pub Date : 2025-10-01 DOI: 10.1016/S0271-5317(25)00128-9

引用次数: 0

首页上一页

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Nutrition Research

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.

﹀